Skip to content


Volume 10 Supplement 1

de Senectute: Age and Health Forum

  • Meeting abstract
  • Open Access

Macular functional changes in patients with neovascular age-related macular degeneration receiving ranibizumab therapy (lucentis)

  • 1,
  • 1,
  • 1 and
  • 1
BMC Geriatrics201010 (Suppl 1) :A77

  • Published:


  • Vascular Endothelial Growth Factor
  • Visual Acuity
  • Ranibizumab
  • Intravitreal Injection
  • Weekly Assessment


Vascular endothelial growth factor (VEGF) is considered to play an essential role in the pathogenesis of age-related macular degeneration due to its vascular permeability-inducing and angiogenic properties. Ranibizumab, a small antibody fragment designed to competitively bind all VEGF isoforms, passes after intravitreal injection into all retinal layers reaching the retinal pigment epithelium-choroid complex. The actions of ranibizumab result in reduced cell proliferation, reduced formation of new blood vessels, and minimization of vascular leakage. The aim of this study was to evaluate the prospectively macular function in in patients with neovascular age-related macular degeneration (AMD) patients undergoing repeated intravitreal injections of Ranibizumab therapy (Lucentis).

Materials and methods

Twenty patients affected by AMD (age range 60-72 years) were enrolled in the study. Inclusion criteria for this study were: evidence of age-related macular degeneration, angiographic evidence of predominantly classic and occult CNV extending under the center of the foveal avascular zone, absence of coexisting ocular disease. Patients enrolled showed baseline visual acuity ranged 1-0.84 logMAR, central microperimetric (Nikon MP-1) sensitivity 2 to 10 dB. Each patient underwent weekly assessments, for three months, of visual acuity, microperimetry and focal electroretinogram (FERG), performed according to a published technique.


Following the first intravitreal injection, mean visual acuity (Figure 1), microperimetric sensitivity (Figure 2) and FERG amplitude (Figure 3) increased steadily from baseline values over the treatment period, with further improvements following each intravitreal injection (P<0.001).
Figure 1
Figure 1

Visual acuity (ETDRS)

Figure 2
Figure 2

Central Microperimetric

Figure 3
Figure 3

FERG amplitude


Ranibizumab therapy can improve central macular function in patients with predominantly classic and occult CNV.

Authors’ Affiliations

Department of Ophthalmology, Magna Græcia University, Catanzaro, 8100, Italy


  1. Arden GB: Vaegan. Electroretinograms evoked in man by local uniform orpatterned stimulation. J Physiol. 1983, 341: 85-104.PubMedPubMed CentralView ArticleGoogle Scholar
  2. Kourlas H, Abrams P: Ranibizumab for the treatment of neovascular age-related macular degeneration: a review. Clin Ther. 2007, 29 (9): 1850-61. 10.1016/j.clinthera.2007.09.008.PubMedView ArticleGoogle Scholar
  3. McKibbin M, Papastefanou V, Matthews B, Cook H, Downey L: Ranibizumab monotherapy for sub-foveal haemorrhage secondary to choroidal neovascularisation in age-related macular degeneration. Eye. 2009Google Scholar


© Scalzo et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd.